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Abstract Nonabsorbable disaccharides have been the main-
stay of treatment for hepatic encephalopathy since introduced
into clinical practice in 1966. Their beneficial effects reflect
their ability to reduce the intestinal production/absorption of
ammonia. A recent Cochrane review confirmed the efficacy
and safety of nonabsorbable disaccharides for the treatment
and prevention of hepatic encephalopathy in patients with
cirrhosis. The findings were robust and support the use of
nonabsorbable disaccharides as a first line treatment for hepat-
ic encephalopathy, in this patient population, and for its
prevention.
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The non-absorbable disaccharide, lactulose, was first intro-
duced into clinical practice, for the treatment of hepatic en-
cephalopathy, in 1966. The second generation non-absorbable
disaccharide, lactitol, was introduced in the mid-1980s. These
non-absorbable disaccharides have become the mainstay of
treatment for this condition.
These synthetic disaccharides are broadly classified
as osmotic laxatives but have also been classified as
prebiotics, a generic term referring to agents that induce
the growth and/or activity of commensal micro-organ-
isms. They are also often referred to as functional foods
placing them conceptually intermediate between foods
and drugs.
In this review the mechanism of action of the non-
absorbable disaccharides will be reviewed; their clinical effi-
cacy and safety for the treatment of hepatic encephalopathy
will be examined and the barriers to their use, in this context,
explored.
Mechanism of action
The human small intestinal mucosa does not possess enzymes
capable of splitting these synthetic disaccharides into their
consistent parts. Thus, they are not processed or absorbed in
the small intestine but pass unchanged into the large intestine.
There they are extensively metabolized by colonic bacteria to
their constituent monosaccharides and then to volatile fatty
acids and hydrogen. Their beneficial effects reflect their abil-
ity to reduce the intestinal production/absorption of ammonia,
which is achieved in four ways:
(i) A laxative effect: the colonic metabolism of the non-
absorbable disaccharides results in an increase in
intraluminal gas formation, an increase in intraluminal
osmolality, a reduction in intraluminal pH, and an overall
decrease in transit time;
(ii) Bacterial uptake of ammonia: the intraluminal changes
in pH result in a leaching of ammonia from the circula-
tion into the colon. The colonic bacteria use the released
volatile fatty acids as substrate and proliferate. In doing
so, they use the trapped colonic ammonia as a nitrogen
source for protein synthesis. The increase in bacterial
numbers additionally ‘bulks’ the stool and contributes
to the cathartic effect (Weber et al. 1987);
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(iii) Reduction of intestinal ammonia production: nonab-
sorbable disaccharides inhibit glutaminase activity
and interfere with the intestinal uptake of gluta-
mine and its subsequent metabolism to ammonia
(van Leeuwen et al. 1988);
(iv) Beneficial effects on the gut microbiome: cirrhosis is
associated with dysbiosis and changes to the colonic
mucosal microbiome (Qin et al. 2014); there is also
evidence of further changes in the gut microbiome in
patients with hepatic encephalopathy (Bajaj et al.
2012). Non-absorbable disaccharides can beneficially
affect microbiota composition (Riggio et al. 1990;
Bajaj et al. 2012).
Clinical efficacy
A Cochrane review, published in 2004, found insufficient ev-
idence to recommend the use of non-absorbable disaccharides
for the treatment of hepatic encephalopathy in patients with
cirrhosis (Als-Nielsen et al. 2004). However, there were a
number of methodological issues with this review including:
the selection of the included trials; the reporting of bias do-
mains; and the lack of statistical power-all of which weakened
the strength of the conclusions.
In 2014, the European and American Associations for the
Study of the Liver (EASL/AASLD) published a joint practice
guideline in which they recommended lactulose as the treat-
ment of choice for overt hepatic encephalopathy and for sec-
ondary prevention after an index event (Vilstrup et al. 2014).
They did not recommend routine treatment for minimal hepat-
ic encephalopathy but stated that exceptions could be made,
on a case-by-case basis, if driving skills, work performance,
quality of life or cognitive function were impaired. They did
not recommend primary prophylaxis for the prevention of
hepatic encephalopathy except in patients ‘known to be at
high risk’ which was not otherwise defined. The guideline
mentions that lactitol is preferred in some centres but did not
comment on the relative efficacy and safety of the two agents.
The authors of the EASL/AASLD guideline based their
recommendations on clinical experience and on a formal re-
view and analysis of recently published literature selecting
studies for inclusion based on the appropriateness of the study
design, a relevant number of participants and confidence in
the participating centre and investigators. There is clearly a
potential risk of bias in this approach.
The apparent discrepant views provided by the original
Cochrane review (Als-Nielsen et al. 2004) and the latest
EASL/AASLD practice guideline (Vilstrup et al. 2014)
prompted a further review, under the Cochrane banner, of
the role of non-absorbable disaccharides in patients with cir-
rhosis and hepatic encephalopathy (Gluud et al. 2016). A total
of 38 randomized clinical trials involving 1828 participants
were included and the analyses provided moderate quality
evidence that use of non-absorbable disaccharides is associat-
ed with beneficial effects on hepatic encephalopathy, mortal-
ity, and serious adverse events when used to treat overt hepatic
encephalopathy, minimal hepatic encephalopathy and to pre-
vent hepatic encephalopathy. Lactulose and lactitol were
equally as effective. More specifically the review showed:
Hepatic encephalopathy
Treatment with non-absorbable disaccharides was associated
with a significant beneficial effect on hepatic encephalopathy
with a number needed to treat (NNT) of six (Fig. 1).
Mortality
Treatment was associated with a significant beneficial effect
on survival with a NNT of 19; (Table 1).
Serious adverse events
The risk of serious adverse events, including: liver failure,
serious infections, spontaneous bacterial peritonitis, variceal
haemorrhage and hepatorenal syndrome was significantly re-
duced with a NNT of six (Table 2):
The findings of this updated review (Gluud et al. 2016)
contrast with those of the previous Cochrane review mainly
because of the increased number of trials now available for
review and the overall quality of the evidence. The findings
endorse the EASL/AASLD guideline with regard to the
treatment of overt hepatic encephalopathy and the pre-
vention of recurrence after an index event but found
additional evidence to support the treatment of minimal
hepatic encephalopathy and for primary prophylaxis.
Barriers to treatment
The non-absorbable disaccharides have a laxative effect and
their use can be associated with nausea, bloating, diarrhoea
Table 1 Beneficial effects of non-absorbable disaccharides on
mortality in randomized clinical trials, by type of hepatic encephalopathy
Type of hepatic
encephalopathy
RR (95 % CI) Trials (n) Patients (n)
Overt 0.36 (0.14–0.94) 6 172
Minimal 0.82 (0.24–2.86) 12 647
Prevention 0.63 (0.40–0.98) 6 668
Overall 0.59 (0.40–0.87) 24 1487
(adapted from Gluud et al. 2016)
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and flatulence. This is more of a problem with lactulose syrup,
which is contaminated with other sugars, than it is with the
crystalline lactulose preparation or with lactitol. Adjusting the
dosage to produce two semi-soft stools a day will optimize the
beneficial effects whilst minimizing the side-effects. Many
patients adapt well to long-term use of these agents seemingly
developing tolerance to the side-effects over time; others,
however, do not.
There is very little information on long-term compliance
with treatment but little doubt that non-adherence is a major
factor in ‘treatment failure’ (Bajaj et al. 2010; Volk et al.
2012). There are, however, factors other than side-effects that
can affect compliance, including: (i) on the patients’ part: a lack
of awareness of the need for long-term treatment; an inability to
effectively titrate the treatment dosage and the inconvenience of
treatment when away from home; and, (ii) on the physicians’
part: a failure to explain the multiple ways in which non-
absorbable disaccharides produces their beneficial effects; an
undue focus on the need to pass two semi-soft stools/day often
resulting in the belief by the patient that as long as this is
achieved there is no real need to take the medication; and the
assumption that patients will comply with treatment and hence
a failure to continuously check adherence.
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Fig. 1 Beneficial effects of non-
absorbable disaccharides on
hepatic encephalopathy in
randomized clinical trials against
placebo/no intervention, by type
of encephalopathy (adapted from
Gluud et al. 2016)
Table 2 Beneficial effects of non-absorbable disaccharides on serious
adverse events in randomized clinical trials
Serious adverse events RR (95 % CI) Trials (n) Patients (n)
Liver failure 0.35 (0.11–1.15) 4 241
Spontaneous bacterial
peritonitis
0.86 (0.32–2.30) 2 278
Variceal haemorrhage 0.46 (0.28–0.98) 9 681
Hepatorenal syndrome 0.47 (0.21–1.04) 3 278
Overall 0.47 (0.36–0.60) 24 1487
(adapted from Gluud et al. 2016)
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Outstanding issues
Non-absorbable disaccharides are an effective and safe treat-
ment for hepatic encephalopathy in patients with cirrhosis.
However, more trials, undertaken to rigorous standards and
with clinically meaningful outcomes, are needed to inform
decision making. In particular long-term trials are needed to
assess the cost-benefit and cost-effectiveness of treating min-
imal hepatic encephalopathy and for primary prevention of
hepatic encephalopathy.
More information on long term-compliance with treatment,
outside of clinical trials, is needed and the reasons for non-
adherence determined. This information should then be used
to inform educational and support systems for patients, their
caregivers and physicians to optimize treatment adherence
and hence benefit.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if
changes were made.
References
Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides
for hepatic encephalopathy: systematic review of randomised trials.
BMJ 328(7447):1046–1052
Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM (2010) Predictors
of the recurrence of hepatic encephalopathy in lactulose-treated
patients. Aliment Pharmacol Ther 31(9):1012–1017
Bajaj JS, Gillevet PM, Patel NR, Ahluwalia V, Ridlon JM,
Kettenmann B, Schubert CM, Sikaroodi M, Heuman DM,
Crossey MM, Bell DE, Hylemon PB, Fatouros PP, Taylor-
Robinson SD (2012) A longitudinal systems biology analysis
of lactulose withdrawal in hepatic encephalopathy. Metab
Brain Dis 27(2):205–215
Gluud LL, Vilstrup H, Morgan MY (2016) Nonabsorbable disac-
charides versus placebo/no intervention and lactulose versus
lactitol for the prevention and treatment of hepatic encepha-
lopathy in people with cirrhosis. Cochrane Database Syst Rev
May 6(5):CD003044
Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao
J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy SP,
Leonard P, Yuan C, Ding W, Chen Y, Hu X, Zheng B, Qian G, Xu
W, Ehrlich SD, Zheng S, Li L (2014) Alterations of the human gut
microbiome in liver cirrhosis. Nature 513(7516):59–64
Riggio O, VarrialeM, Testore GP, Di Rosa R, Di Rosa E,MerliM, Romiti
A, Candiani C, Capocaccia L (1990) Effect of lactitol and lactulose
administration on the fecal flora in cirrhotic patients. J Clin
Gastroenterol 12:433–436
van Leeuwen PA, van Berlo CL, Soeters PB (1988) New mode of action
for lactulose. Lancet 1(8575–6):55–56
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD,
Weissenborn K, Wong P (2014) Hepatic encephalopathy in chronic
liver disease: 2014 practice guideline by the American Association
for the Study of Liver Diseases and the European Association for the
Study of the liver. Hepatology 60(2):715–735
Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS (2012) Hospital
readmissions among patients with decompensated cirrhosis. Am J
Gastroenterol 107(2):247–252
Weber FL, Banwell JG, Fresard KM, Cummings JH (1987) Nitrogen in
fecal bacterial fibre, and soluble fractions of patients with cirrhosis:
effects of lactulose and lactulose plus neomycin. J Lab Clin Med
110(3):259–263
1364 Metab Brain Dis (2016) 31:1361–1364
